- $49.40m
- $56.18m
- $26.49m
- 80
- 54
- 89
- 88
Annual income statement for ImmuCell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.3 | 19.2 | 18.6 | 17.5 | 26.5 |
| Cost of Revenue | |||||
| Gross Profit | 6.86 | 8.66 | 7.65 | 3.87 | 7.94 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.9 | 19 | 20.9 | 22.9 | 28.1 |
| Operating Profit | -0.537 | 0.257 | -2.3 | -5.38 | -1.64 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -0.069 | -2.49 | -5.77 | -2.15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.02 | -0.078 | -2.49 | -5.77 | -2.16 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.02 | -0.078 | -2.49 | -5.77 | -2.16 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.02 | -0.078 | -2.49 | -5.77 | -2.16 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.214 | -0.008 | -0.323 | -0.775 | -0.263 |